Mode
Text Size
Log in / Sign up

Monoclonal stool antigen test shows high accuracy for H. pylori detection in chronic atrophic gastritis patients.

Monoclonal stool antigen test shows high accuracy for H. pylori detection in chronic atrophic gastri…
Photo by Wengang Zhai / Unsplash
Key Takeaway
Consider using monoclonal SAT for H. pylori detection in high-risk CAG patients due to high specificity and strong consistency.

This prospective primary care study enrolled 287 patients diagnosed with chronic atrophic gastritis (CAG). The primary objective was to assess the diagnostic accuracy of a monoclonal stool antigen test (SAT) against a reference standard that combined histology and urea breath test (UBT). Secondary outcomes included sensitivity, specificity, positive predictive value, overall accuracy, and agreement measured by kappa statistics.

The SAT demonstrated an area under the ROC curve of 0.858. Overall sensitivity was 75.9% and specificity was 96.1%. The study observed that performance metrics were positively correlated with the severity of gastric atrophy. Specifically, specificity in high-risk patients was 96.77% compared to 95.77% in low-risk patients. Positive predictive value was 95.24% in high-risk patients versus 93.48% in low-risk patients. Overall accuracy was 89.29% in high-risk patients versus 86.05% in low-risk patients.

Agreement between the SAT and the reference standard yielded a kappa of 0.72 overall. Agreement was 0.77 in high-risk patients and 0.69 in low-risk patients. No adverse events, serious adverse events, discontinuations, or tolerability data were reported in this study. The authors note that the test is a reliable non-invasive tool for detecting H. pylori in CAG, with performance improving in advanced atrophy populations.

Key takeaway: Consider using monoclonal SAT for H. pylori detection in high-risk CAG patients due to high specificity and strong consistency.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
Background/aimsDiagnosing active Helicobacter pylori (H. pylori) infection in patients with chronic atrophic gastritis (CAG) remains challenging. The monoclonal stool antigen test (SAT) offers a non-invasive alternative to endoscopic methods. This study aimed to evaluate the diagnostic accuracy of SAT in CAG and to analyze its performance in relation to the severity of gastric atrophy.MethodsIn this prospective study, 287 patients with CAG underwent SAT, urea breath test, serology, and histology. Patients were stratified into low-risk and high-risk groups based on gastric cancer progression risk. SAT was assessed against a reference standard combining histology and UBT.ResultsThe area under the ROC curve for SAT was 0.858. SAT showed a sensitivity of 75.9% and a specificity of 96.1%. In high-risk patients, SAT demonstrated comparable specificity (96.77% vs. 95.77%) and positive predictive value (95.24% vs. 93.48%) to those in low-risk patients, with numerically higher accuracy (89.29% vs. 86.05%). Consistency analysis revealed substantial agreement between SAT and the reference standard overall (κ=0.72), with stronger agreement in the high-risk patients (κ=0.77) than in the low-risk patients (κ=0.69).ConclusionsMonoclonal SAT is a reliable non-invasive tool for detecting H. pylori in CAG, exhibiting high specificity and strong diagnostic consistency. Its performance is positively correlated with the severity of gastric atrophy, supporting its preferential use in high-risk, advanced atrophy populations.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.